Ariad Pharmaceuticals (ARIA) Stock Falls Despite Revenue Beat

NEW YORK (TheStreet) -- Ariad Pharmaceuticals  (ARIA) fell Wednesday despite the company's first-quarter results that beat analysts' expectations.

The company reported net loss of $49.8 million, or 27 cents a share, compared to $64.7 million, or 36 cents a share, in the same period one year earlier. Revenue rose 81.5% year over year to $11.8 million for the quarter. These figures beat the Capital IQ consensus estimate of a loss of 32 cents a share on revenue of $10.41 million.

Research and development expenses also decreased 31% to $12.7 million due to reduced clinical trial and manufacturing costs.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Despite this, the stock was down 5.78% to $6.68 at 10:48 a.m.

ARIA Chart

ARIA data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)